-
New to The Street to Broadcast Tonight on Bloomberg at 6:30 PM EST - Show #744 Featuring Virtuix Holdings (NASDAQ:VTIX), Neonc Technologies Holdings (NASDAQ:NTHI), Medicus Pharma (NASDAQ:MDCX), YY Gro
-
Vivos Therapeutics (VVOS) PT Lowered to $2.50 at H.C. Wainwright
-
New to The Street to Broadcast on Fox Business on Monday, April 13, Featuring Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holdings (NASDAQ:YYGH), Vivos Therapeutics (NASDAQ:
-
New to The Street Broadcasts Show #740 on Bloomberg Television at 6:30 PM EST Featuring Medicus (MDCX), Acme Markets- Canton Foundation, Alpha Ton Capital (ATON), and Virtuix Holdings (NASDAQ:VTIX)
-
Vivos Therapeutics gains Nevada insurance coverage, cuts costs
-
New to The Street to Broadcast Executive Leadership Interviews Featuring Medicus Pharma Ltd. (NASDAQ:MDCX), CitroTech (NYSE:CITR), Vivos Therapeutics, Inc. (NASDAQ:VVOS), and Virtuix Holdings ($VTIX)
-
New to The Street to Broadcast Executive Leadership Interviews Tonight at 6:30 PM EST on Bloomberg Television Across the U.S., MENA and Latin America
-
New to The Street to Broadcast Show #726 on Bloomberg at 6:30 PM EST Featuring Vivos Therapeutics (NASDAQ:VVOS), Aeries Technology (NASDAQ:AERT), Virtuix Holdings (NASDAQ:VTIX), and Stardust Power (NA
-
Vivos Therapeutics partners with SoundHealth to distribute sleep devices
-
VIVOS Therapeutics, Inc. ($VVOS) Signs 12-Part Media Series with New to The Street
-
Vivos Therapeutics raises $4.64 million from warrant exercises
-
Vivos Therapeutics raises $4.64 million through warrant exercise
-
Vivos Therapeutics opens affiliated sleep center in Auburn Hills
-
Vivos Therapeutics (VVOS) PT Lowered to $5.50 at Ascendiant Capital
-
Vivos Therapeutics (VVOS) Misses Q3 EPS by 1c
-
H.C. Wainwright Starts Vivos Therapeutics (VVOS) at Buy
-
Vivos Therapeutics (VVOS) Misses Q2 EPS by 16c
-
Vivos Therapeutics hires two executives to support expansion
-
Vivos Therapeutics (VVOS) Receives Medicare Approval for VidaSleep Oral Appliance
-
Vivos Therapeutics (VVOS) highlights positive trial results for treatment of OSA with Daytime-Nighttime Appliance
-
Vivos Therapeutics (VVOS) Completes Acquisition of The Sleep Center of Nevada
-
Alliance Global Partners Downgrades Vivos Therapeutics (VVOS) to Neutral
-
Vivos Therapeutics (VVOS) Misses Q1 EPS by 4c
-
Vivos Therapeutics (VVOS) Files $50M Mixed Shelf
-
Vivos Therapeutics (VVOS) Prices 709K Share Offering at $4.935/sh
-
Vivos Therapeutics (VVOS) Granted CPT Coverage and Reimbursement Codes for All Vivos CARE Oral Medical Devices
-
Vivos Therapeutics (VVOS) Prices 1.36M Share Offering at $3.15/sh
-
Vivos Therapeutics (VVOS) Receives FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring
-
Vivos Therapeutics (VVOS) PT Raised to $6.60 at Ascendiant Capital
-
Vivos Therapeutics (VVOS) Misses Q2 EPS by 60c
-
Vivos Therapeutics (VVOS) Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and Distribution Model
-
Vivos Therapeutics (VVOS) Closes $7.5M ATM

